Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

This year. We're going Beyond.

Why the Baby Bunting Group (ASX:BBN) share price is soaring

The Baby Bunting Group Ltd (ASX: BBN) share price is flying today after the retailer handed down its full-year FY20 results.

After a difficult few years dealing with a high cost and saturated store network, COVID-19 may have been the antidote Baby Bunting was looking for.

The company reported 11.8% sales growth on 2019 as investors turned to e-commerce. The biggest contributor to the $402 million sales of baby products was 39.1% growth in online sales, including click and collect, with the second half particularly strong, up 66.1%.

This resulted in a 34.1% increase in net profit to $19.3 million and a 25% increase in the dividend to 6.4 cents per share, sending the share price higher.

Importantly, the company announced that all stores remained open and that it was not receiving any JobKeeper payments, so there is nothing hidden in this announcement as far as stimulus is concerned.

Summary: Reporting season standout, little wonder the company is now sitting at all-time highs.

For a detailed write-up on Baby Bunting’s result, check out this article from Rask Media’s Jaz Harrison: Baby Bunting (ASX:BBN) FY20 reveals 34% operating profit growth

This report was written by Drew Meredith, Financial Adviser and Director of Wattle Partners. To get in contact with Drew, click here to visit the Wattle Partners website.

Got $1,000? Try our #1 growth stock...

Rask's top analyst has just identified his #1 'MedTech' stock idea for 2021 and beyond. This is a SERIOUS growth stock.

CLICK HERE to get the ASX stock ticker code, 3,500-word analysis and ASX founder interview!

Our expert investment reports are 100% free.

Simply click here or enter your email below. We'll send you the report.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Got $1,000? Try this...

Rask's top analyst has just identified his #1 'MedTech' stock idea for 2021 and beyond. This is a SERIOUS growth stock.

CLICK HERE to get the ASX stock ticker code, 3,500-word analysis and ASX founder interview!

Our expert investment reports are 100% free.

Simply click here or the button below. We'll email you the report.

Disclosure: Drew Meredith is the author of this post. He may maintain positions in the securities mentioned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading: